194 related articles for article (PubMed ID: 31473871)
1. Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.
Toh Y; Numasaki H; Tachimori Y; Uno T; Jingu K; Nemoto K; Matsubara H
Esophagus; 2020 Jan; 17(1):25-32. PubMed ID: 31473871
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.
Nemoto K; Kawashiro S; Toh Y; Numasaki H; Tachimori Y; Uno T; Jingu K; Matsubara H
Esophagus; 2020 Apr; 17(2):122-126. PubMed ID: 31912332
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy and radiotherapy alone in patients with esophageal cancer aged 80 years or older based on the Comprehensive Registry of Esophageal Cancer in Japan.
Jingu K; Numasaki H; Toh Y; Nemoto K; Uno T; Doki Y; Matsubara H
Esophagus; 2020 Jul; 17(3):223-229. PubMed ID: 32088786
[TBL] [Abstract][Full Text] [Related]
4. The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909.
Hironaka S; Komori A; Machida R; Ito Y; Takeuchi H; Ogawa G; Kato K; Onozawa M; Minashi K; Yano T; Nakamura K; Tsushima T; Hara H; Nozaki I; Ura T; Chin K; Fukuda H; Kitagawa Y
Esophagus; 2020 Oct; 17(4):417-424. PubMed ID: 32342253
[TBL] [Abstract][Full Text] [Related]
5. [Chemoradiotherapy for esophageal cancer].
Fujita H; Sueyoshi S; Tanaka T; Sasahara H; Matono S; Yamana H; Shirouzu K; Suzuki G; Hayabuchi N
Gan To Kagaku Ryoho; 2003 Jul; 30(7):937-43. PubMed ID: 12894707
[TBL] [Abstract][Full Text] [Related]
6. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
8. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
9. Differences in treatment and survival between elderly patients with thoracic esophageal cancer in metropolitan areas and other areas.
Motoyama S; Maeda E; Iijima K; Anbai A; Sato Y; Wakita A; Nagaki Y; Fujita H; Minamiya Y; Higashi T
Cancer Sci; 2021 Oct; 112(10):4281-4291. PubMed ID: 34288283
[TBL] [Abstract][Full Text] [Related]
10. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
[TBL] [Abstract][Full Text] [Related]
11. Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy.
Kim HJ; Suh YG; Lee YC; Lee SK; Shin SK; Cho BC; Lee CG
Cancer Res Treat; 2017 Jul; 49(3):669-677. PubMed ID: 27737537
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
13. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.
Nishimura Y; Koike R; Ogawa K; Sasamoto R; Murakami Y; Itoh Y; Negoro Y; Itasaka S; Sakayauchi T; Tamamoto T
Int J Clin Oncol; 2012 Feb; 17(1):48-54. PubMed ID: 21607829
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
[TBL] [Abstract][Full Text] [Related]
15. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
17. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
[TBL] [Abstract][Full Text] [Related]
18. Impact of certification status of the institute and surgeon on short-term outcomes after surgery for thoracic esophageal cancer: evaluation using data on 16,752 patients from the National Clinical Database in Japan.
Motoyama S; Yamamoto H; Miyata H; Yano M; Yasuda T; Ohira M; Kajiyama Y; Toh Y; Watanabe M; Kakeji Y; Seto Y; Doki Y; Matsubara H
Esophagus; 2020 Jan; 17(1):41-49. PubMed ID: 31583502
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999-2001.
Kenjo M; Uno T; Murakami Y; Nagata Y; Oguchi M; Saito S; Numasaki H; Teshima T; Mitsumori M
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):357-63. PubMed ID: 19735863
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group.
Okawa T; Dokiya T; Nishio M; Hishikawa Y; Morita K
Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):623-8. PubMed ID: 10524414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
